ArticleBMC cancer2021
Urinary Exosomal miRNAs as biomarkers of bladder Cancer and experimental verification of mechanism of miR-93-5p in bladder Cancer.
Article in BMC cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 6 syntheses or guidelines pooled it, 58 citations in OpenAlex.
- Integrated assessment of non-invasive diagnostic tools for bladder cancer: a network meta-analysis.Frontiers in oncology · 2025Pooled it
- The diagnostic accuracy of urine-derived exosomes for bladder cancer: a systematic review and meta-analysis.World journal of surgical oncology · 2024Pooled it
- Exosomal noncoding RNAs as noninvasive biomarkers in bladder cancer: a diagnostic meta-analysis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024Pooled it
- The role of microRNAs in non-invasive diagnosis of bladder cancer: a systematic review.Einstein (Sao Paulo, Brazil) · 2024Pooled it
- Diagnostic and prognostic potential of exosome non-coding RNAs in bladder cancer: a systematic review and meta-analysis.Frontiers in oncology · 2024Pooled it
- Meta-analysis of the diagnostic value of exosomal microRNAs in renal cell carcinoma.Frontiers in oncology · 2024Pooled it
- Liquid biopsy in bladder cancer: towards precision oncology.Journal of translational medicine · 2026Review
- Clinical utility of urinary microRNA (miR-1273g-3p) in male patients with detrusor underactivity.World journal of urology · 2026Article
- Liquid biopsies in precision oncology for older adults with cancer.NPJ precision oncology · 2026Review
- Clinical utility of cell-free urine miR-93-5p, miR-191-5p, miR-31-5p for invasive urothelial carcinoma detection and immune signature-based subtyping.BMC urology · 2026Article
- Urine-derived induced pluripotent stem cells for non-invasive diagnosis of bladder cancer.Journal of Cancer · 2026Review
- Decoding the role of exosomes in bladder cancer: focusing on tumor progression and immune microenvironment modulation.Frontiers in oncology · 2026Review
- Nanorobots and Exosomes: Driving the New Frontier for Bladder Tumors through Non-Coding RNAs.Oncology research · 2026Review
- MiRNA expression analysis from circulating exosomes in Barrett's esophagus patients with visceral obesity.Scientific reports · 2025Article
- Comparison of microRNA-21 expression in bladder cancer tumor with normal-appearing adjacent tissue and healthy controls.International urology and nephrology · 2025Article
- Plasma-Derived Small Extracellular Vesicles miR- 182 - 5p Is a Potential Biomarker for Diagnosing Major Depressive Disorder.Molecular neurobiology · 2025Article
- The role of exosomes in bladder cancer immunotherapy.Journal of the National Cancer Center · 2025Review
- AAAGUGC Seed-Containing miRNAs: Master Regulators of Cancer Pathways and Therapeutic Resistance.MicroRNA (Shariqah, United Arab Emirates) · 2025Review
- Extracellular vesicles-derived extracellular RNA in bladder cancer: current progress and future prospects.Therapeutic advances in medical oncology · 2025Review
- Unraveling the multifaceted roles of extracellular vesicles in bladder cancer: diagnostic insights and therapeutic opportunities.Frontiers in oncology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBladder cancer (BC) is one of the most common malignancies globally. Early diagnosis of it can significantly improve patients' survival and quality of life. Urinary exosomes (UEs)-derived miRNAs might be a promising biomarker for BC detection.
methodA total of 12 patients with BC and 4 non-cancerous participants (as healthy control) were recruited from a single center between March 2018 and December 2019 as the discovery set. Midstream urine samples from each participants were collected and high-throughput sequencing and differentially expression analysis were conducted. Combined with miRNA expression profile of BC tissue from The Cancer Genome Atlas (TCGA), miRNAs biomarkers for BC were determined. Candidate miRNAs as biomarkers were selected followed by verification with a quantitative reverse-transcription polymerase chain reaction assay in an independent validation cohort consisting of 53 BC patients and 51 healthy controls. The receiver-operating characteristic (ROC) curve was established to evaluate the diagnostic performance of UE-derived miRNAs. The possible mechanism of miRNAs were revealed by bioinformatic analysis and explored in vitro experiments.
resultsWe identified that miR-93-5p, miR-516a-5p were simultaneously significantly increased both in UEs from BC compared with healthy control and BC tissue compared with normal tissue, which were verified by RT-qPCR in the validation cohort. Subsequently, the performance to discover BC of the miR-93-5p, miR-516a-5p was further verified with an area under ROC curve (AUC) of 0.838 and 0.790, respectively, which was significantly higher than that of urine cytology (AUC = 0.630). Moreover, miR-93-5p was significantly increased in muscle-invasive BC compared with non-muscle-invasive BC with an AUC of 0.769. Bioinformatic analysis revealed that B-cell translocation gene 2(BTG2) gene may be the hub target gene of miR-93-5p. In vitro experiments verified that miR-93-5p suppressed BTG2 expression and promoted BC cells proliferation, invasion and migration.
conclusionUrine derived exosomes have a distinct miRNA profile in BC patients, and urinary exosomal miRNAs could be used as a promising non-invasive tool to detect BC. In vitro experiments suggested that miR-93-5p overexpression may contribute to BC progression via suppressing BTG2 expression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.